These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33368935)

  • 1. A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.
    Shah M; Stolbov L; Yakovleva T; Tang W; Sokolov V; Penland RC; Boulton D; Parkinson J
    Diabetes Obes Metab; 2021 Apr; 23(4):991-1000. PubMed ID: 33368935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
    Tang W; Leil TA; Johnsson E; Boulton DW; LaCreta F
    Diabetes Obes Metab; 2016 Mar; 18(3):236-40. PubMed ID: 26510924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
    Watada H; Shiramoto M; Ueda S; Tang W; Asano M; Thorén F; Kim H; Yajima T; Boulton DW; Araki E
    Diabetes Obes Metab; 2019 Apr; 21(4):876-882. PubMed ID: 30499157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
    Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
    Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
    Plosker GL
    Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
    Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J
    Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
    Zhang L; Feng Y; List J; Kasichayanula S; Pfister M
    Diabetes Obes Metab; 2010 Jun; 12(6):510-6. PubMed ID: 20518806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
    van Haalen HG; Pompen M; Bergenheim K; McEwan P; Townsend R; Roudaut M
    Clin Drug Investig; 2014 Feb; 34(2):135-46. PubMed ID: 24243529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
    Mellander A; Billger M; Johnsson E; Träff AK; Yoshida S; Johnsson K
    Clin Drug Investig; 2016 Nov; 36(11):925-933. PubMed ID: 27461213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
    Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
    Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
    Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
    Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin: glucuretic action and beyond.
    Balakumar P; Sundram K; Dhanaraj SA
    Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
    Sokolov V; Yakovleva T; Ueda S; Parkinson J; Boulton DW; Penland RC; Tang W
    Diabetes Obes Metab; 2019 Apr; 21(4):829-836. PubMed ID: 30456904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.